FDA‍ to Replace Animal Testing with ‍AI for Monoclonal Antibody Therapies

Updated April 10, 2025

The Food and Drug Management announced Thursday it will replace animal testing⁣ with human-relevant methods, such as AI-based computational models, for evaluating monoclonal antibody‍ therapies and other drugs. The agency expects this new approach to improve drug safety, accelerate evaluations, reduce animal experimentation, and lower research and progress costs, potentially leading to lower drug prices.

The FDA will promptly begin encouraging the inclusion of data from New Approach Methodologies (NAMs) in investigational new drug (IND) applications. These methodologies include AI-based toxicity models,cell lines,and organoid toxicity testing. The agency also plans to use pre-existing, real-world safety‍ data from countries with comparable regulatory standards to determine drug efficacy.

According to the FDA, a roadmap outlining the changes was also released Thursday.

“For ⁤to long, drug manufacturers⁢ have performed additional animal testing of drugs⁣ that have data in broad human⁣ use internationally. This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,” said FDA Commissioner Martin ‍A. Makary.

Makary added that leveraging AI,⁢ human organ models, and real-world human data will lead to‍ safer treatments, faster⁣ results, reduced‍ R&D costs, and lower drug⁣ prices.

The FDA⁢ highlighted several key benefits of replacing animal⁤ testing in monoclonal antibody safety evaluations. Advanced computer simulations and⁢ AI can predict a⁣ drug’s ⁣behavior and potential side effects.Human-based lab models, such as organoids and organ-on-a-chip systems,⁣ can mimic human organs to⁢ test drug safety more effectively. The agency will also update guidelines to ‍allow consideration of data from these new methods, potentially streamlining review for companies that submit strong ‍safety data from non-animal tests.

The FDA believes these modern techniques will speed ⁢up drug development, allowing⁢ monoclonal antibody therapies to reach patients more quickly without compromising safety. This move also reaffirms the FDA’s role as a global leader in modern regulatory science, encouraging the adoption of innovative and humane testing methods.

The FDA will partner with agencies like the National Institutes of Health and the Department ⁣of Veterans Affairs to accelerate the validation and adoption ⁣of these innovative methods through ‍the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM).The FDA and its partners will host a public workshop later this‍ year to discuss the roadmap and gather stakeholder input. The FDA also plans to launch a pilot program allowing select monoclonal⁤ antibody developers to use a primarily non-animal-based testing strategy,under close FDA consultation. Findings from this study will inform broader‍ policy changes and guidance updates.

Commissioner Makary noted the far-reaching⁢ significance of this proposal. “For patients, it means a more efficient pipeline for novel treatments. ‍It also means an added margin‍ of safety, as human-based test systems may better predict real-world outcomes. For animal welfare, it represents a major step toward ending the⁤ use of ⁢laboratory animals in drug testing.Thousands of animals, including dogs and primates, could eventually be ⁢spared each year as these new methods take root.”

What’s next

The FDA aims to launch a pilot program in the coming year,allowing select monoclonal antibody ‍developers to use a primarily non-animal-based testing strategy,under close FDA consultation. Findings from ⁣an accompanying pilot study will⁤ inform broader policy changes and guidance updates expected to roll out in⁢ phases.